SHANGHAI, April 8, 2026 /PRNewswire/ -- On March 12, 2026, the first implant of the ProStyle M® Transcatheter Mitral Valve System (ProStyle M®) was successfully completed under pure ultrasound guidance as part of its confirmatory clinical study. The device is independently developed by KingstronBio Technology (Changshu) Co., Ltd. (KingstronBio). The procedure was performed by Professor Wang Chunsheng and Professor Wei Lai of the Department of Cardiac Surgery, Zhongshan Hospital Affiliated to Fud

Novel approach to engineering complex microbial traits generates tens of millions of gene combinations, enabling gain-of-function traits beyond those observed from individual genes SAN DIEGO, April 8, 2026 /PRNewswire/ -- Primrose Bio, Inc. (Primrose), a company with proprietary biologic manufacturing technologies, today announced the publication of a peer-reviewed study in the Proceedings of the National Academy of Sciences (PNAS), a leading scientific journal, demonstrating a combinatorial gen

MUMBAI, India and NAPLES, Fla., April 8, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg. The company also received tentative appro

DELRAY BEACH, Fla., April 8, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Gastrointestinal Stent Market is projected to grow from about USD 0.62 billion in 2026 to USD 0.82 billion by 2031, at a CAGR of 5.7%. Browse 480 market data Tables and 65 Figures spread through 500 Pages and in-depth TOC on "Gastrointestinal Stent Market - Global Forecast to 2031" Gastrointestinal Stent Market Size & Forecast: Market Size Available for Years: 2025–2031 2026 Market Size: USD 0.62 billion 2031

Tinostamustine Now Enrolling in GBM AGILE, a Registrational-Intent Phase 2/3 Adaptive Platform Trial for Patients with Glioblastoma LARKSPUR, Calif. and STAMFORD, Conn., April 8, 2026 /PRNewswire/ -- The Global Coalition for Adaptive Research (GCAR) and Purdue Pharma L.P. (Purdue) today announced the activation of investigational tinostamustine in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447), a pioneering, international adaptive platform trial designed t

Former DARPA/NIWC Pacific leader brings over a decade of experience supporting $500M+ in federal R&D programs HOUSTON, April 8, 2026 /PRNewswire/ -- EverGlade, a national advisory firm that helps innovators navigate the federal funding ecosystem, announced that Patrick Sims, PhD, has joined the firm as a Managing Consultant. Dr. Sims brings 10+ years of experience supporting the Department of Defense, including extensive work with DARPA's Biological Technologies Office (BTO) and Small Business P

HALIFAX, NS, April 8, 2026 /PRNewswire/ - ABK Biomedical, Inc. and COR Development are proud to announce a strategic partnership to develop a state-of-the-art GMP manufacturing facility in Cartwright Business Park, Ashland, Missouri. This strategic project will provide the long-term future commercial scale production of Eye90 microspheres®, a designated FDA breakthrough technology currently in development for the treatment of liver cancer. As a leader in specialized commercial building, Coil Con

As dementia cases rise globally, more physicians and researchers are pointing to early intervention to improve patient outcomes Published in the Journal of Alzheimer's Disease, results show the brief digital screener built from two Creyos cognitive tasks can identify individuals at risk for cognitive impairment in minutes Researchers analyzed cognitive performance data from thousands of individuals, accurately detecting Alzheimer's cases 100% of the time TORONTO, April 8, 2026 /PRNewswire/ -- Cr

Amigo and Heal sign partnership agreement to jointly pursue clinical AI opportunities across Saudi Arabia Heal to lead localization and provider engagement across the Kingdom with Amigo delivering clinical AI technology and agent engineering expertise NEW YORK, April 8, 2026 /PRNewswire/ -- Amigo (amigo.ai), the platform for building and training patient-facing clinical agents, and Heal (heal.com.sa), a health innovation company operating across Saudi Arabia and the United Arab Emirates, today

First GMP manufacturing license granted to a manufacturing facility in China with four 20,000 liter-scale bioreactors, marking an important milestone in Altruist's expanding service capabilities. Only two months from facility qualification to licensure, demonstrating the company's commitment to outstanding technical capabilities and a rigorous quality management system that upholds international standards. HANGZHOU, China, April 8, 2026 /PRNewswire/ -- Altruist Biologics, an Innovent Biologics